Switzerland
Personalised cancer vaccines make breakthrough as Swiss pharma weighs its position
The first successful Phase III trial of a personalised mRNA cancer vaccine has renewed hopes for treatments tailored to individual tumours. Swiss researchers and pharmaceutical companies are assessing whether the country can compete in the rapidly advancing field.
3 days ago · 1 source

